PharmaCyte Biotech

PMCB52

Penny Stock

$1.99arrow_drop_up4.73%$0.09

Penny Stock

PMCB52

$1.99

arrow_drop_up4.73%$0.09

Penny Stock

Performance History

Key Stats
Open	$1.91
Prev. Close	$1.90
EPS	-1.80
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$14.64M
PE Ratio	-

	LOW	HIGH
Day Range	1.77	1.98
52 Week Range	1.39	2.60

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.80

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About PharmaCyte Biotech (PMCB)

PharmaCyte Biotech, Inc. (PMCB) is a biotechnology company focused on developing cellular therapies for cancer and diabetes. The company's primary goal is to develop a treatment for advanced, inoperable pancreatic cancer, a highly lethal disease with limited treatment options. PharmaCyte's approach involves the encapsulation of genetically modified human cells that convert a chemotherapy drug into its active form when implanted near the tumor. This targeted approach aims to minimize the side effects associated with chemotherapy while maximizing its therapeutic effect.

In addition to its pancreatic cancer program, PharmaCyte is also working on developing a therapy for diabetes. The company is utilizing its proprietary Cell-in-a-Box(R) technology, which encapsulates live cells in a protective casing to protect them from the immune system. By combining this technology with genetically modified cells that produce insulin, PharmaCyte aims to develop a long-lasting, implantable treatment for diabetes. This approach could potentially offer a significant improvement over traditional insulin injections.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Joshua N. Silverman
Headquarters: Las Vegas
Employees: 2
Exchange: NASDAQ

Keep an eye on PharmaCyte Biotech

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is PharmaCyte Biotech's (PMCB) price per share?

The current price per share for PharmaCyte Biotech (PMCB) is $1.99. The stock has seen a price change of $0.09 recently, indicating a 4.74% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for PharmaCyte Biotech (PMCB)?

For PharmaCyte Biotech (PMCB), the 52-week high is $2.6, which is 30.65% from the current price. The 52-week low is $1.39, the current price is 43.17% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is PharmaCyte Biotech (PMCB) a growth stock?

PharmaCyte Biotech (PMCB) has shown an average price growth of 0.41% over the past three years. It has received a score of 21 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying PharmaCyte Biotech as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is PharmaCyte Biotech (PMCB) stock price performance year to date (YTD)?

As of the latest data, PharmaCyte Biotech (PMCB) has a year-to-date price change of -8.92%. Over the past month, the stock has experienced a price change of 5.85%. Over the last three months, the change has been -9.95%. Over the past six months, the figure is 2.05%.

help

Is PharmaCyte Biotech (PMCB) a profitable company?

PharmaCyte Biotech (PMCB) has a net income of $333.76K, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$8.52M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of PharmaCyte Biotech (PMCB)?

PharmaCyte Biotech (PMCB) has a market capitalization of $14.65M. The average daily trading volume is 18.7K, indicating the stock's liquidity and investor engagement.

News

HEALTHCARE INVESTMENTS

8/27/2024

Pancreatic Cancer Treatment Market Size Worth USD 10.53 Billion by 2032 Driven by Rising Prevalence of Obesity, Smoking, and Alcohol Consumption | Research by SNS Insider

2/9/2023

Meta Platforms Announces $40 Billion Share Buyback - Buyback Wednesdays

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

MAJOR SHAREHOLDER ANNOUNCEMENTS

10/7/2022

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

8/14/2021

Wall Street Breakfast: What Moved Markets

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

About PharmaCyte Biotech (PMCB)

Keep an eye on PharmaCyte Biotech

Frequently Asked Questions

What is PharmaCyte Biotech's (PMCB) price per share?

What is the 52-week high and low for PharmaCyte Biotech (PMCB)?

Is PharmaCyte Biotech (PMCB) a growth stock?

What is PharmaCyte Biotech (PMCB) stock price performance year to date (YTD)?

Is PharmaCyte Biotech (PMCB) a profitable company?

What is the market capitalization of PharmaCyte Biotech (PMCB)?

News

Sign up for our newsletter

Take Your Investments to a Whole New Level